Zynlonta
What Zynlonta is used for
Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Zynlonta
- Active substance
- loncastuximab tesirine
- Disease area
- Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX22
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Zynlonta
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zynlonta used for?
Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
What is the active substance in Zynlonta?
Zynlonta contains loncastuximab tesirine.
Who makes Zynlonta?
The EU marketing authorisation holder is Swedish Orphan Biovitrum AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU